Greenwich LifeSciences Says Two Abstracts Accepted For AACR Annual Meeting 2026 As Phase III FLAMINGO-01 Trial Evaluates Fast Track GLSI-100 To Prevent Breast Cancer Recurrence
Greenwich LifeSciences, Inc. -0.61%
Greenwich LifeSciences, Inc. GLSI | 22.82 | -0.61% |
Greenwich LifeSciences Says Two Abstracts Accepted For AACR Annual Meeting 2026 As Phase III FLAMINGO-01 Trial Evaluates Fast Track GLSI-100 To Prevent Breast Cancer Recurrence